Martin Traber

Martin Traber is a bio-pharmaceutical professional with 20 years of experience in clinical development and medical affairs. Neurosciences are the focus including Alzheimer’s Disease, Multiple Sclerosis, and Spinal Muscular Atrophy. Other therapeutic areas covered encompass Immunology, Rheumatology and Oncology. Since 2017, Martin has been working at Roche serving a Global Medical Lead for Alzheimer’s Disease focusing on Roche’s monoclonal antibody Gantenerumab (currently in phase 3 clinical development).

Martin Traber studied human medicine at the University of Basel with educational stays in Marseille, Verona, Guadalajara, Copenhagen and Vienna. Martin holds a doctorate of human medicine, and the title as board certified specialist in pharmaceutical medicine. Further, Martin received a master of public health, with a special focus in health economics, from the London School of Hygiene and Tropical Medicine. Between 2008 und 2009, Martin Traber completed an educational program in general management at the University of St. Gall, Switzerland.

As President of the Swiss Society of Pharmaceutical Medicine, Martin Traber is advocating for the research and knowledge hub Switzerland. Teaching assignments at the University of Zurich and Basel, and serving as examiner at the European Center of Pharmaceutical Medicine complete Martin Traber’s extracurricular activities.